Black men face earlier and higher prostate cancer risk. Learn why the PSA screening conversation should begin between ages 40 ...

Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...

When I had my prostate removed in September 2023, I believed the worst was behind me. After months of tests, scans and ...

Getting to a prostate cancer diagnosis used to mean at least two separate procedures. The process included a scan first, followed by a biopsy, often occurring weeks apart. That two-step process made ...

Despite guidelines on bone protection, more than 40% of patients with metastatic castration-resistant prostate cancer received no bone-modifying agents, a US study found. The use has declined in ...

Bone scan indexes (BSIs) are frequently applied in Japan, Europe and the USA. The BONENAVI (Japan) and aBSI (Europe and USA) software programs were developed based on different training and validation ...

NEW YORK, June 8, 2026 /PRNewswire/ -- Just two days after his minimally invasive prostate cancer treatment at NYU Langone Health, Broadway performer André De Shields, 80, was back on stage preparing ...

Jill Biden is giving an update on her husband's health a year after former President Joe Biden was diagnosed with cancer. During a June 1 interview on NBC's "Today" to promote her new memoir, the ...

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients, a critical indicator of a ...

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients a critical indicator of a ...

8.9% of patients on combo had little to no cancer at surgery vs 1% on hormone therapy alone Treatment regimen cut disease recurrence or death risk by 20% Researchers call data 'paradigm changing' J&J ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...